🔎 Trials Near Me

Home › Post-COVID Conditions (Long COVID) › Illinois

Pag-aaral pangklinika para sa Post-COVID Conditions (Long COVID) sa Illinois

13 pag-aaral para sa Post-COVID Conditions (Long COVID) ang naghahanap ng mga kalahok sa mga site sa Illinois.

Mga Lungsod sa Illinois

Opisyal na teksto ng pag-aaral (English)

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

  • Rush University Medical Center ( Site 3748), Chicago
  • Duly Health and Care ( Site 3799), Lombard
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06667700

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

  • Research Site, Evanston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05624450

A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised

  • Northwestern Memorial Hospital, Chicago
  • Northwestern University Feinberg School of Medicine, Chicago
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07013474

Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

  • Illinois Research Network (ILLInet), University of Illinois Chicago, Chicago
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06631287

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

  • Koch Family Medicine, Morton
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06679140

Dime La VerDAD: Verify, Debunk, and Disseminate

  • University of Chicago, Chicago
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT06417762

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
Nagre-recruitPhase 3
Lahat ng edad · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT03808922

Cognitive-Sensorimotor Function in Long-COVID

  • Jesse Brown VA Medical Center, Chicago, IL, Chicago
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update May 8, 2026 · NCT06850350

Dysbiosis & Long COVID

  • The University of Chicago, Chicago
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Mar 2, 2026 · NCT06825819

A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection

  • University of Chicago, Chicago
Nagre-recruitPhase 4Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2025 · NCT06008860

EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease

  • University of Chicago Medical Center, Chicago
Nagre-recruitPhase 3
Edad 0 hanggang 17 · Lahat ng kasarian · Na-update Hul 17, 2025 · NCT05261139

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

  • University of Illinois Health, Chicago
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 12, 2024 · NCT02735707

Convalescent Plasma as a Possible Treatment for COVID-19

  • University of Illinois at Chicago, Chicago
Nagre-recruitPhase 2
Edad 40 pataas · Lahat ng kasarian · Na-update Hun 22, 2020 · NCT04442191

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.